Active Ingredient History
Folic Acid is a B complex vitamin containing a pteridine moiety linked by a methylene bridge to para-aminobenzoic acid, which is joined by a peptide linkage to glutamic acid. Conjugates of Folic Acid are present in a wide variety of foods, particularly liver, kidneys, yeast and leafy green vegetables. Commercially available Folic Acid is prepared synthetically. Folic Acid occurs as a yellow or yellowish-orange crystalline powder and is very slightly soluble in water and insoluble in alcohol. Aqueous solutions of Folic Acid are heat sensitive and rapidly decompose in the presence of light and/or riboflavin; solutions should be stored in a cool place protected from light. Folic Acid is effective in the treatment of megaloblastic anemias due to a deficiency of Folic Acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. Folic Acid is relatively nontoxic in man. Rare instances of allergic responses to Folic Acid preparations have been reported and have included erythema, skin rash, itching, general malaise, and respiratory difficulty due to bronchospasm. Endocyte is developing an intravenous (IV) formulation of folic acid, called Neocepri®, which is intended for the diagnosis of positive folate receptor-positive status in patients with ovarian cancer when administered prior to the radioactive medicine, technetium Tc99m Etarfolatide. The benefits of Neocepri® are its ability to reduce the background activity observed on single photon emission computed tomography (SPECT) imaging in most normal, nontarget tissues (e.g. intestines, liver, kidney, spleen), thereby improving the image quality of the scans. The product had been granted orphan drug designation in the EU. Endocyte had filed a conditional marketing authorization application (CMA) with the European Medicines Agency (EMA) for Neocepri®. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia, Megaloblastic (approved 1947)
Abortion, Habitual (Phase 4)
Abortion, Induced (Phase 3)
Adenoma (Phase 2/Phase 3)
Aging (Phase 2)
Alzheimer Disease (Phase 3)
Anemia ()
Anemia, Sickle Cell (Phase 2/Phase 3)
Angioplasty (Phase 2/Phase 3)
Anovulation (Phase 4)
Anterior Wall Myocardial Infarction (Phase 2/Phase 3)
Aortic Valve Stenosis (Phase 2)
Arsenic (Phase 4)
Arsenic Poisoning (Phase 2)
Arterial Occlusive Diseases (Phase 2/Phase 3)
Arthritis (Phase 2)
Arthritis, Experimental (Phase 2)
Arthritis, Rheumatoid (Phase 4)
Asthenozoospermia (Phase 2/Phase 3)
Atherosclerosis (Phase 4)
Autistic Disorder (Phase 2)
Blood Loss, Surgical (Phase 3)
Blood Pressure (Phase 2)
Breast Neoplasms (Phase 2/Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Transitional Cell (Phase 3)
Cardiovascular Diseases (Phase 4)
Cerebral Infarction (Phase 3)
Cleft Lip (Phase 3)
Cleft Palate (Phase 3)
Cognitive Dysfunction (Phase 2)
Colonic Neoplasms (Phase 2)
Colonic Polyps (Phase 2)
Colorectal Neoplasms (Phase 3)
Congenital Abnormalities (Phase 3)
Contraception (Phase 3)
Contraceptives, Oral (Phase 1)
Contrast Media (Phase 2/Phase 3)
Coronary Artery Disease (Phase 3)
Coronary Disease (Phase 2/Phase 3)
Coronavirus Infections (Phase 3)
COVID-19 (Phase 3)
Delivery, Obstetric (Phase 4)
Dementia (Phase 4)
Depression (Phase 4)
Diabetes, Gestational (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetic Nephropathies (Phase 2/Phase 3)
Diabetic Retinopathy (Phase 4)
Diarrhea (Phase 2)
Drug Evaluation (Phase 2)
Drug Interactions (Phase 1)
Dyspepsia (Phase 4)
Endothelial Cells (Phase 2)
Epilepsy (Phase 3)
Esophageal Neoplasms (Phase 2)
Feeding and Eating Disorders (Phase 4)
Folic Acid Deficiency (Phase 2/Phase 3)
Gingival Overgrowth (Phase 3)
Glycogen Storage Disease Type II (Phase 3)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 3)
Heart Failure (Phase 4)
Heart Rate (Phase 1)
Hepatitis C (Phase 4)
HIV (Phase 2)
HIV Infections (Phase 2)
Hodgkin Disease (Phase 1/Phase 2)
Homocysteine (Phase 2/Phase 3)
Hypercholesterolemia (Phase 4)
Hyperemesis Gravidarum (Phase 4)
Hyperhomocysteinemia (Phase 4)
Hypertension (Phase 4)
Hypophosphatasia (Phase 4)
Infant, Low Birth Weight (Phase 4)
Infant Mortality (Phase 3)
Infant Nutrition Disorders (Phase 4)
Infant, Premature, Diseases (Phase 4)
Infertility (Phase 2)
Infertility, Female (Phase 3)
Infertility, Male (Phase 4)
Inflammation (Phase 4)
Inflammatory Bowel Diseases (Phase 4)
Intestinal Neoplasms (Phase 4)
Iron Deficiencies (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 4)
Lung Neoplasms (Phase 2/Phase 3)
Lupus Erythematosus, Systemic (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, T-Cell (Phase 3)
Lymphoma, T-Cell, Cutaneous (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 1/Phase 2)
Malaria (Phase 4)
Malnutrition (Phase 4)
Menstruation Disturbances (Phase 4)
Mental Health (Phase 2/Phase 3)
Mesothelioma (Phase 2)
Metabolic Syndrome (Phase 4)
Morning Sickness (Phase 4)
Mucositis (Phase 2)
Mutation (Phase 2)
Mycobacterium tuberculosis (Phase 3)
Mycosis Fungoides (Phase 1)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 2)
Nausea (Phase 4)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 4)
Nervous System Malformations (Phase 3)
Neural Tube Defects (Phase 3)
Obesity (Phase 4)
Obstetric Labor, Premature (Phase 3)
Oligospermia (Phase 2/Phase 3)
Oral Ulcer (Early Phase 1)
Osteoarthritis (Phase 4)
Osteoporosis (Phase 1)
Ovarian Neoplasms (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 3)
Parkinson Disease (Phase 2)
Perinatal Death (Phase 3)
Perinatal Mortality (Phase 3)
Periodontal Attachment Loss (Early Phase 1)
Periodontal Diseases (Early Phase 1)
Periodontitis (Early Phase 1)
Pharmacokinetics (Phase 1)
Plasma (Phase 2)
Pleura (Phase 2)
Pneumonia (Phase 2)
Poisoning (Phase 2)
Polycystic Ovary Syndrome (Phase 4)
Polyps (Phase 2/Phase 3)
Postpartum Hemorrhage (Phase 4)
Precancerous Conditions (Phase 2)
Pre-Eclampsia (Phase 3)
Pregnancy (Phase 4)
Pregnancy Complications (Phase 4)
Premature Birth (Phase 3)
Premature Ejaculation (Phase 3)
Premenstrual Dysphoric Disorder (Phase 4)
Premenstrual Syndrome (Phase 4)
Prostatic Neoplasms (Phase 2)
Psoriasis (Phase 1)
ras Proteins (Phase 2)
Renal Dialysis (Phase 4)
Renal Insufficiency, Chronic (Phase 3)
Reproductive Medicine (Phase 3)
SARS-CoV-2 (Phase 2/Phase 3)
Schizophrenia (Phase 4)
Sezary Syndrome (Phase 1)
Small Cell Lung Carcinoma (Phase 3)
Smoking Cessation (Phase 2)
Stillbirth (Phase 3)
Stomach Diseases (Phase 3)
Stomach Neoplasms (Phase 2)
Stroke (Phase 4)
Therapeutic Equivalency (Phase 1)
Tobacco Use Disorder (Phase 2)
Uremia (Phase 4)
Ureteral Neoplasms (Phase 3)
Urinary Bladder Neoplasms (Phase 3)
Urologic Diseases (Phase 4)
Uterine Cervical Neoplasms (Phase 2)
Ventricular Remodeling (Phase 2/Phase 3)
Vomiting (Phase 4)
Waldenstrom Macroglobulinemia (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
